Patents by Inventor Xiong Cai

Xiong Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINE BASED EGFR INHIBITORS
    Publication number: 20140005391
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Application
    Filed: December 6, 2012
    Publication date: January 2, 2014
    Applicant: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai
  • TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20130338167
    Abstract: The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below: These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and may further act as HDAC inhibitors. The invention further relates to the use of these tartrate salts in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Application
    Filed: May 22, 2013
    Publication date: December 19, 2013
    Applicant: CURIS, INC.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8604044
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: December 10, 2013
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould, Haixiao Zhai
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 8586605
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 19, 2013
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Substituted 2-Aminoacetamides and the Use Thereof
    Publication number: 20130303568
    Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
    Type: Application
    Filed: April 22, 2013
    Publication date: November 14, 2013
    Inventors: Nancy C. LAN, Yan Wang, Sui Xiong Cai
  • CDK inhibitors containing a zinc binding moiety
    Patent number: 8563741
    Abstract: The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: October 22, 2013
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Haixiao Zhai
  • Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8518910
    Abstract: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a ?-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: August 27, 2013
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai, Rudi Bao
  • Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
    Patent number: 8461157
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: June 11, 2013
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
  • Quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8455506
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: June 4, 2013
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould
  • Substituted 2-aminoacetamides and the use thereof
    Patent number: 8426431
    Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: April 23, 2013
    Assignee: Purdue Neuroscience Company
    Inventors: Nancy C. Lan, Yan Wang, Sui Xiong Cai
  • Tyrosine kinase inhibitors containing a zinc binding moiety
    Patent number: 8426419
    Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: April 23, 2013
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
    Publication number: 20130090335
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: March 30, 2012
    Publication date: April 11, 2013
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
  • Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
    Patent number: 8367663
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: February 5, 2013
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Cheng-Jung Lai, Changgeng Qian
  • Quinazoline based EGFR inhibitors
    Patent number: 8349856
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: January 8, 2013
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai
  • SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20120322844
    Abstract: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Application
    Filed: August 23, 2012
    Publication date: December 20, 2012
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 8324240
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: December 4, 2012
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
    Patent number: 8273785
    Abstract: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 25, 2012
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20120237508
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: March 20, 2012
    Publication date: September 20, 2012
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Method of treating brain cancer
    Patent number: 8258145
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: September 4, 2012
    Assignee: Myrexis, Inc.
    Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Nilantha Sudath Sirisoma
  • CDK INHIBITORS
    Publication number: 20120165335
    Abstract: The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 28, 2012
    Inventors: Changgeng Qian, Xiong Cai, Haixiao Zhai